Liraglutide (Victoza), developed by Novo Nordisk, is a pioneering GLP-1 receptor agonist that has reshaped the management of type 2 diabetes and obesity through its proven efficacy in glycemic control, weight reduction, and cardiovascular risk reduction. Victoza and Saxenda both contain liraglutide, but they are distinct formulations and brands. Victoza is indicated for type 2 diabetes (with cardiovascular outcome data), while Saxenda at a higher dose is approved for chronic weight management.
